CA2359360A1 - Methode de criblage in vitro permettant d'identifier des partenaires de liaison selective pour recepteurs 5-ht5 - Google Patents

Methode de criblage in vitro permettant d'identifier des partenaires de liaison selective pour recepteurs 5-ht5 Download PDF

Info

Publication number
CA2359360A1
CA2359360A1 CA002359360A CA2359360A CA2359360A1 CA 2359360 A1 CA2359360 A1 CA 2359360A1 CA 002359360 A CA002359360 A CA 002359360A CA 2359360 A CA2359360 A CA 2359360A CA 2359360 A1 CA2359360 A1 CA 2359360A1
Authority
CA
Canada
Prior art keywords
receptors
binding affinity
binding
ht1d
partner
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002359360A
Other languages
English (en)
Other versions
CA2359360C (fr
Inventor
Francisco Javier Garcia-Ladona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2359360A1 publication Critical patent/CA2359360A1/fr
Application granted granted Critical
Publication of CA2359360C publication Critical patent/CA2359360C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des partenaires de liaison sélectifs pour les récepteurs 5-HT5, ainsi que des procédés d'identification et de caractérisation de tels partenaires de liaison, notamment des procédés de criblage. Elle concerne également des compositions pharmaceutiques contenant ces partenaires de liaison, et leur utilisation pour le traitement d'affections cérébrovasculaires, telles que la migraine.
CA2359360A 1999-01-11 2000-01-11 Methode de criblage in vitro permettant d'identifier des partenaires de liaison selective pour recepteurs 5-ht5 Expired - Fee Related CA2359360C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19900674.1 1999-01-11
DE19900674A DE19900674A1 (de) 1999-01-11 1999-01-11 Bindungspartner für 5-HT5-Rezeptoren zur Migränebehandlung
PCT/EP2000/000142 WO2000041472A2 (fr) 1999-01-11 2000-01-11 Partenaires de liaison pour les recepteurs 5-ht5 utilises pour le traitement de la migraine

Publications (2)

Publication Number Publication Date
CA2359360A1 true CA2359360A1 (fr) 2000-07-20
CA2359360C CA2359360C (fr) 2012-11-27

Family

ID=7893919

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2359360A Expired - Fee Related CA2359360C (fr) 1999-01-11 2000-01-11 Methode de criblage in vitro permettant d'identifier des partenaires de liaison selective pour recepteurs 5-ht5

Country Status (8)

Country Link
EP (1) EP1144050A2 (fr)
JP (1) JP2002540063A (fr)
CN (1) CN1321635C (fr)
AU (1) AU2289100A (fr)
CA (1) CA2359360C (fr)
DE (1) DE19900674A1 (fr)
MX (1) MXPA01006986A (fr)
WO (1) WO2000041472A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921406B2 (en) 2005-08-21 2014-12-30 AbbVie Deutschland GmbH & Co. KG 5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors
US9296697B2 (en) 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US5360735A (en) * 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
FR2693200B1 (fr) * 1992-07-01 1994-08-19 Inst Nat Sante Rech Med Nouveaux polypeptides ayant une activité de récepteur sérotoninergique, acides nucléiques codant pour ces polypeptides et utilisations.
FR2701265B1 (fr) * 1993-02-09 1995-04-07 Inst Nat Sante Rech Med Nouveaux polypeptides ayant une activité de récepteur sérotoninergique, acides nucléiques codant pour ces polypeptides et utilisations.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921406B2 (en) 2005-08-21 2014-12-30 AbbVie Deutschland GmbH & Co. KG 5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors
US9296697B2 (en) 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors

Also Published As

Publication number Publication date
CN1342070A (zh) 2002-03-27
WO2000041472A3 (fr) 2001-10-11
AU2289100A (en) 2000-08-01
EP1144050A2 (fr) 2001-10-17
CA2359360C (fr) 2012-11-27
JP2002540063A (ja) 2002-11-26
MXPA01006986A (es) 2002-09-18
DE19900674A1 (de) 2000-07-13
WO2000041472A2 (fr) 2000-07-20
CN1321635C (zh) 2007-06-20

Similar Documents

Publication Publication Date Title
BR9910332A (pt) Polipeptìdio, composição, método para purificação de polipeptìdio a partir de uma composição e método para purificação de um anticorpo a partir de uma composição
FR2767070B1 (fr) Composition visqueuses aqueuses, limpides ou non, pour la fabrication de capsules molles et de capsules dures, et procede de fabrication de films pour de telles capsules
WO1999061471A3 (fr) Proteines transmembranaires humaines
PT831879E (pt) Metodo para identificar ou isolar uma molecula e moleculas assim identificadas
BR0009323A (pt) Anticorpos humanos que ligam a il-12 humana e métodos para a produção
NO20011891L (no) Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon
BR9902643A (pt) Emulsão de óleo de silicone, composição e método de fabricação
WO2000015793A3 (fr) Proteines gpcr humaines
DE69942063D1 (de) Antagonisten von 'hedgehog' und 'patched' zur inhibierung des wachstums und der differenzierung von zellen und geweben, als auch deren verwendungen
WO2000012711A3 (fr) Proteines membranaires de canal humaines
WO2000009709A3 (fr) Proteases et proteines associees
WO2000018922A3 (fr) Proteines humaines associees a des glucides
ATE258310T1 (de) Testverfahren für collagenpeptid
FR2816410B1 (fr) Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
FR2774988B1 (fr) Procede de purification de la prpres a partir d'un echantillon biologique et ses applications
WO2003039491A8 (fr) Nouveaux isoformes de l'inhibiteur de la croissance de cellules endotheliales vasculaires
CA2359360A1 (fr) Methode de criblage in vitro permettant d'identifier des partenaires de liaison selective pour recepteurs 5-ht5
ATE269544T1 (de) Rezeptor für bacillus thuringiensis toxin
WO1999049038A3 (fr) Proteines de fixation du calcium humaines
WO2003008553A3 (fr) Proteines associees a la croissance, a la differenciation et a la mort cellulaires
ES2192199T3 (es) Ligandos de la familia eph biologicamente activos.
BG100863A (en) Fibrin-specifil antibody and its use as an antithrombotic agent
WO2000031263A3 (fr) Proteines associees a la gtpase
WO2000028045A3 (fr) Hydrolases humaines
WO2002044368A1 (fr) Nouvelles proteines du recepteur couple a la proteine g et leurs adn

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150112